Hoffmann-La Roche Ltd. (Switzerland) and AbbVie Inc. (US) are Leading Players in the Antibody Therapeutics Market
The global antibody therapeutics market is projected to reach USD 479.0 billion by 2028 from USD 247.3 billion in 2023, at a CAGR of 14.1% during the 2023-2028 forecast period. Factors supporting the market growth include the growing initiatives towards advancements in antibody engineering, growing demand for oncology antibody therapeutics and growing clinical pipeline focus on antibody therapeutics among others. However, stringent regulations might restrain growth to a certain extent.
The market for antibody therapeutics market is consolidated, with key players strategizing to capture the majority of the market. Prominent players in the market are F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (US), Johnson & Johnson (US), Merck KGaA (Germany), Bristol-Myers Squibb (US), AstraZeneca (UK), Sanofi (France), Regeneron Pharmaceuticals, Inc. (US), Novartis AG (Switzerland), Amgen, Inc. (US), Biogen Inc. (US) among others.
To know about the assumptions considered for the study download the pdf brochure
F. Hoffmann-La Roche Ltd. (Switzerland) is one of the key established players in the antibody therapeutics market. The company contributes significantly to the antibody therapeutics market. Additionally, the company also has a strong geographic presence with distribution channels across North America, Europe, Asia Pacific, Latin America, the Middle East and Africa regions. The company focuses on innovation through significant R&D investments with ~USD 16.8 billion in R&D noted in 2022. However, the company might experience competitive threats owing to the growing number of players with novel antibody therapeutics in the market. Major product examples offered by Novartis AG include- TECENTRIQ (atezolizumab), COLUMVI (glofitamab-gxbm), LUNSUMIO (mosunetuzumab-axgb), VABYSMO (faricimab-svoa), OCREVUS (ocrelizumab) among others.
AbbVie Inc. (US) is another key player in the antibody therapeutics market. The company aims to enhance its position in the antibody therapeutics market through developments including strategic collaborations. Immunology is the major therapeutic area of focus for AbbVie in the anibody therapeutics field. The company also focuses on innovating through investments in R&D noted to be ~USD 6.5 billion in 2022. Additionally, the company faces competitive threats from other key players such as F. Hoffmann-La Roche Ltd., and Johnson & Johnson in this market. Antibody therapeutics products offered by AbbVie Inc. include- HUMIRA (adalimumab), and SKYRIZI (risankizumab-rzaa).
Johnson & Johnson (J&J) (US) is also a well-established player in the antibody therapeutics market. The company currently offers more than seven commercialized antibody therapeutics products through its company Janssen Pharmaceuticals. J&J has majorly focused on innovation and commercialization of antibody therapeutics with an investment of ~ USD 11.6 billion in R&D in 2022. J&J’s major strengths include a wide geographic reach and a strong brand image. The company has geographic presence across major regions, including North America, Europe, and other regions. Major product examples offered by Gilead Sciences, Inc. include RYBREVANT (amivantamab-vmjw), TALVEY (talquetamab-tgvs), TECVAYLI (teclistamab-cqyv), TREMFYA (guselkumab), DARZALEX (daratumumab), SYLVANT (siltuximab), SIMPONI (golimumab) among others.
Related Reports:
Antibody Therapeutics Market by Format (Monoclonal, Polyclonal, Antibody Fragment, Bispecific), Disease area (Oncology, Autoimmune & Inflammatory, Neurology, Hematology, Infectious), Source (Human, Chimeric), Route (IV, SC) - Global Forecast to 2028
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
